About iCardiac Technologies
iCardiac Technologies is a company based in Rochester (United States) founded in 2006 was acquired by Clario in December 2017. iCardiac Technologies has raised $4 million across 3 funding rounds from investors including Norwest Venture Partners, Clario and Advantage Capital. iCardiac Technologies operates in a competitive market with competitors including Celerion, Altasciences, Ask Gene Pharma, Open Orphan and AWAKN, among others.
- Headquarter Rochester, United States
- SectorsHealthcare
- Website icardiac.com
- Social LinkedIn X
- Acquired by Clario (Dec 2017)
- Total Equity Funding$4M (USD)
in 3 rounds
- InvestorsNorwest Venture Partners
& 5 more
- Acquired byClario
(Dec 2017)
Funding Insights of iCardiac Technologies
iCardiac Technologies has successfully raised a total of $4M across 3 strategic funding rounds. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $4M
- Total Rounds 3
- First Round $4M
(Nov 2006)
- Investors Count 5
All 3 funding rounds of iCardiac Technologies with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Mar 2014 | – | Series C | – | – | |
| Nov 2007 | – | Series B | – | – | |
| Nov 2006 | $4M | Series A | – | – |
6 investors in total: 6 institutional.
Investors in iCardiac Technologies
iCardiac Technologies has secured backing from 6 investors, including venture fund and institutional investors. Prominent investors backing the company include Norwest Venture Partners, Clario and Advantage Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Venture capital and growth equity firm providing investments and resources to entrepreneurs in various sectors. | 1961 | nvp.com | Menlo Park, United States | |
Private equity investment firm | – | advantagecap.com | New Orleans, United States | |
- | – | trillium-group.com | - | |
US private equity investments are managed by Stonehenge Capital. | – | stonehengecapital.com | Baton Rouge, United States | |
- | – | stonehengegrowthequity.com | - | |
CRO focused on providing clinical trial supply services for biopharma sector | 1972 | clario.com | Philadelphia, United States |
Investor details for iCardiac Technologies
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of iCardiac Technologies
4 dated milestones of iCardiac Technologies across 11 years, from founding to its latest funding, stage changes and deals.
- Founded iCardiac Technologies is founded.
- Funding First funding round of $4.0M.
- Funding Latest funding round, Series C,.
- Exit Acquired by Clario.
Competitors of iCardiac Technologies
iCardiac Technologies operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Celerion, Altasciences, Ask Gene Pharma, Open Orphan and AWAKN, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| celerion.com | 2010 | Lincoln, United States | – | 940 | Early clinical research services are provided for drug development. | |
| altasciences.com | 2015 | Laval, Canada | – | 249 | Early phase clinical research services are provided in North America. | |
| ask-gene.com | 2012 | Camarillo, United States | $20M | 24 | Biosimilars and biosuperiors are developed and commercialized in biotechnology. | |
| openorphan.com | 2017 | London, United Kingdom | – | 218 | Provider of testing vaccines & antivirals and CRO pharmaceutical services | |
| awaknlifesciences.com | 2020 | Portishead, United Kingdom | – | 49 | CRO focused on early stage clinical trial research | |
| avancecro.com | 2018 | Thebarton, Australia | – | – | Clinical development services are provided to pharmaceutical clients worldwide. | |
| clerkenwellhealth.com | 2020 | London, United Kingdom | $2.33M | – | CRO focused on conducting early stage clinical development of psychedelic medicines | |
| spauldingclinical.com | 2007 | West Bend, United States | $1.71M | – | CRO services for Phase I Clinical Trials, and Core ECG lab services for trials from Phase I to IV | |
| hmrlondon.com | 1993 | London, United Kingdom | – | – | CRO which has worked in 670+ trials and specializes in early stage clinical trials |
Detailed competitors of iCardiac Technologies
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Icardiac Technologies
Complete news archive for iCardiac Technologies
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to iCardiac Technologies
10 companies that operate in the same segment as iCardiac Technologies (Biopharma Outsourcing & Drug Delivery), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Developer of integrated contract research development and manufacturing services | 2007 | Bengaluru, Karnataka, India | USD 35.74 M | USD 226.38 M | 1,820 | |
Drug discovery and development services are provided to biopharma sector. | 1993 | Hamburg, Hamburg, Germany | USD 25 M | USD 926.33 M | 4,830 | |
Drug discovery and development services for small molecules are provided. | 2003 | Beijing, China | USD 320 M | – | 476 | |
Suite solutions are provided for payers and healthcare providers. | 1998 | Princeton, New Jersey, United States | USD 255.15 M | USD 374.1 M | 4,490 | |
Wearable insulin infusion systems are developed for diabetes patients. | 2000 | Boston, Massachusetts, United States | USD 120.4 M | USD 2.71 B | 3,900 | |
Developer of small-molecule drugs | 1991 | Los Angeles, California, United States | USD 50 M | USD 348.97 M | 407 | |
Pharmaceutical and biotechnology company | 2005 | Hyderabad, Telangana, India | USD 229.73 M | USD 726.15 M | 12,470 | |
Pharmaceutical products for treating multiple diseases are provided. | 1849 | New York, New York, United States | USD 8 M | USD 266.99 M | 1,770 | |
Provider of laboratory tests for physicians | 1969 | Burlington, Vermont, United States | – | USD 13.95 B | 70,000 | |
India's leading healthcare products distribution platform | 2018 | Mumbai, Maharashtra, India | USD 59.67 M | USD 702.49 M | 4,260 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about iCardiac Technologies
iCardiac Technologies was founded in 2006.
iCardiac Technologies is headquartered in Rochester, United States.
iCardiac Technologies is a funded company, having raised a total of $4M across 3 funding rounds to date. The company's 1st funding round was a Series A of $4M, raised on Nov 2006.
iCardiac Technologies was founded in 2006 in Rochester, United States, within the biopharmaceutical sector. ECG core laboratory services for cardiac safety assessments are offered, utilizing the iClinica platform to analyze data from First-in-Human to Phase III studies, including Thorough QT evaluations. Respiratory and electronic patient-reported outcome services were added through the 2015 acquisition of nSpire Healths clinical trials division. Operations support major biopharma firms alongside smaller entities.
iCardiac Technologies's top competitors include Celerion, Ask Gene Pharma and HMR London.
iCardiac Technologies has 6 investors. Key investors include Norwest Venture Partners, Clario, Advantage Capital, Trillium Group, and Stonehenge Growth Equity Partners.
Yes. iCardiac Technologies was acquired by Clario in December 2017.